Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge

Clinical and Experimental Immunology

Volumn 183, Issue 3, 2016, Pages 441-451

  Mcclain, M T ^a,b,c   Henao, R ^a,d   Williams, J ^b   Nicholson, B ^b   Veldman, T ^a   Hudson, L ^a   Tsalik, E L ^a,b,c   Lambkin Williams, R ^e   Gilbert, A ^e   Mann, A ^e   Ginsburg, G S ^a   Woods, C W ^a,b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Duke University   (United States)

^e Queen Mary BioEnterprises Innovation Centre   (United Kingdom)

Author keywords

Cytokines; Humans; Influenza; Viral infection

Indexed keywords

ALPHA INTERFERON; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CXCL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOWN REGULATION; EXPERIMENTAL INFLUENZA; FEVER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLUENZA A (H3N2); INNATE IMMUNITY; INOCULATION; LEUKOCYTE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTOMICS; UPREGULATION; VIRUS LOAD; VIRUS SHEDDING; ASYMPTOMATIC DISEASE; BLOOD; FEMALE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; MALE; MICROARRAY ANALYSIS; PHYSIOLOGY; TIME FACTOR; VIROLOGY; YOUNG ADULT;

ADULT; ASYMPTOMATIC DISEASES; CHEMOKINE CXCL10; CYTOKINES; DOWN-REGULATION; FEMALE; HEALTHY VOLUNTEERS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INTERLEUKIN-15; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MICROARRAY ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 84958906718     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12736     Document Type: Article

References (27)

1. Lee N, Wong CK, Chan PK et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLOS ONE 2011; 6:e26050.
2. Huang Y, Zaas AK, Rao A et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. PLOS Genet 2011; 7:e1002234.
3. Clark RSB, Carcillo JA, eds. Molecular biology of acute lung injury. Boston/Dordrecht/London: Kluwer Academic Publishers; 2001.
4. Davey RT Jr, Lynfield R, Dwyer DE et al. The association between serum biomarkers and disease outcome in influenza A (H1N1)pdm09 virus infection: results of two international observational cohort studies. PLOS ONE 2013; 8:e57121.
5. Chi Y, Zhu Y, Wen T et al. Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis 2013; 208:1962-7.
6. Wang Z, Zhang A, Wan Y et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 2014; 111:769-74.
7. Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-9.
8. Chan MC, Cheung CY, Chui WH et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6:135.
9. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res 2011; 51:15-25.
10. Bradley-Stewart A, Jolly L, Adamson W et al. Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09. J Clin Virol 2013; 58:100-7.
11. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101:643-9.
12. Memoli MJ, Czajkowski L, Reed S et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015; 60:693-702.
13. Woods CW, McClain MT, Chen M et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLOS ONE 2013; 8:e52198
14. Zaas AK, Chen M, Varkey J et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 2009; 6:207-17.
15. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80.
16. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med 1958; 101:267-78.
17. Leland DS, French MLV. Virus isolation and identification. In: Lennette EH, Halonen P, Murphy FA, eds. Laboratory diagnosis of infectious diseases: principles and practices. New York: Springer-Verlag; 1988. pp 39-59.
18. Yuan XHR, Tsalik EL, Langley R, Carin L. Non-Gaussian discriminative factor models via the max-margin rank-likelihood. Proceedings of the 32nd International Conference on Machine Learning 2015; 15:1254-63.
19. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-6.
20. Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A (H1N1) virus pneumonia. Antivir Ther 2011; 16:237-47.
21. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7.
22. Monteerarat Y, Sakabe S, Ngamurulert S et al. Induction of TNF-alpha in human macrophages by avian and human influenza viruses. Arch Virol 2010; 155:1273-9.
23. Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305-12.
24. Oldstone MB, Rosen H. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol 2014; 378:129-47.
25. Shirey KA, Lai W, Scott AJ et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497:498-502.
26. Lee SM, Yen HL. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res 2012; 96:391-404.
27. Proud D, Turner RB, Winther B et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am J Respir Crit Care Med 2008; 178:962-8.